• Publications
  • Influence
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Importance The incidence and prevalence of neuroendocrine tumors (NETs) are thought to be rising, but updated epidemiologic data are lacking. Objective To explore the evolving epidemiology andExpand
  • 733
  • 40
  • PDF
PD-L1 expression and prognostic impact in glioblastoma.
BACKGROUND Therapeutic targeting of the immune checkpoints cytotoxic T-lymphocyte-associated molecule-4 (CTLA-4) and PD-1/PD-L1 has demonstrated tumor regression in clinical trials, and phase 2Expand
  • 246
  • 13
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis
Importance Minimal residual disease (MRD) refers to the presence of disease in cases deemed to be in complete remission by conventional pathologic analysis. Assessing the association of MRD statusExpand
  • 147
  • 12
  • PDF
Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer.
PURPOSE To determine whether pretreatment CT texture features can improve patient risk stratification beyond conventional prognostic factors (CPFs) in stage III non-small cell lung cancer (NSCLC). Expand
  • 131
  • 8
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
Background Despite a multiplicity of clinical trials testing immune checkpoint inhibitors, the frequency of expression of potential predictive biomarkers is unknown in glioma. Methods In thisExpand
  • 139
  • 8
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.
Glioblastomas are highly infiltrated by diverse immune cells, including microglia, macrophages, and myeloid-derived suppressor cells (MDSCs). Understanding the mechanisms by whichExpand
  • 158
  • 8
  • PDF
Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
BACKGROUND Neuroendocrine tumours (NETs) can secrete bioactive amines into the bloodstream, causing carcinoid syndrome, with symptoms including flushing and diarrhoea. However, carcinoid syndromeExpand
  • 119
  • 7
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
BACKGROUND Expression of programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) across glioma grades is undocumented, and their interactions with commonly expressed genetic andExpand
  • 68
  • 5
MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.
BACKGROUND Antibody therapeutic targeting of the immune checkpoints cytotoxic T-lymphocyte-associated molecule 4 (CTLA-4) and programmed cell death 1 (PD-1) has demonstrated marked tumor regressionExpand
  • 85
  • 4
  • PDF
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors have been increasingly used in cancer therapy. Understanding the treatment-related adverse events ofExpand
  • 126
  • 3